 Cytokine release syndrome monoclonal antibody mice prevention high doses methylprednisolone hamster specific complex murine shares many properties induction cell activation vivo injection entails variety pathologic changes relation systemic release cytokines effects cytokine release syndrome different doses methylprednisolone m-PDS various intervals time mAb administration high doses m-PDS mg/kg mAb complete inhibition systemic release TNF-alpha As pathologic changes hypothermia acute renal tubular necrosis fatty infiltration liver hypoglycemia protective effect m-PDS toxicity reduction mortality rate galactosamine-sensitized mice inhibition release cytokines m-PDS immunosuppression CTL activity alloantigens injection mAb administration high doses glucocorticoids prevents release cytokines acute toxicity mAb Similar protocols mitigation cytokine-release syndrome mAb man